ZYBERNO
Stock Report
Updated Aug 23, 2026

Acurx Pharmaceuticals, Inc. (ACXP)

Healthcare • NASDAQ

$1.47

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
16.0/100
POOR BUSINESS
Acurx Pharmaceuticals, Inc. (ACXP) scores 16/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-124.7%)
Debt-to-Equity (Solvency Risk):GOOD (0.35x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,900.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Acurx Pharmaceuticals, Inc. (ACXP) stock report — Zyberno Score 16/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.47
Market Cap:$6.26M

Valuation Multiples (2)

P/B Ratio:0.77x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$1.56M

Price Action & Momentum (1)

% of 52-Week High:17.6%
B. Profitability Assessment

Return Metrics (5)

ROA:-87.5%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$320.43
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:75.6%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.88x
Quick Ratio:3.88x
Cash Ratio:3.76x

Leverage Analysis (3)

Debt To Equity Ttm:0.35x
Debt-to-Equity Ratio:0.35x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:8,152,031.00
Cash And Cash Equivalents:10,656,386.00
Long Term Debt:$0.00
Net Debt:-$7.82M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$8.32M

Bottom Line Performance (3)

-$7.51M
Income Before Tax:$0.00
Ebitda Ttm:-8,321,602.00

Operating Expenses (5)

Operating Expenses:7,696,325.00
R And D Expense:2,124,502.00
Sga Expense:5,571,823.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$10.98M
Current Assets:$10.98M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,832,746.00
Current Liabilities:2,832,746.00
Long Term Debt:$0.00
Short Term Debt:$2.83M

Equity & Capital (3)

Equity:$8.15M
Retained Earnings:-$79.22M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:2,832,746.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:258,287.00
C. Cash Flow Analysis

Operating Activities (2)

-$6.14M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$3.11M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,500,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.47
-$4.47
Earnings Per Share Ttm:-$1.76

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.59

Book Value & Capital (2)

Book Value Per Share:$1.91
Cash Per Share:2.50

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-7.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:ACXP
Company Name:Acurx Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:4.26M
Shares Outstanding Basic:4.26M
Shares Outstanding Diluted:4.26M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 05:34:05 UTC
Data Timestamp:2026-08-21T23:40:47.038149
Scroll to Top